JP2025016538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025016538A5 JP2025016538A5 JP2024185456A JP2024185456A JP2025016538A5 JP 2025016538 A5 JP2025016538 A5 JP 2025016538A5 JP 2024185456 A JP2024185456 A JP 2024185456A JP 2024185456 A JP2024185456 A JP 2024185456A JP 2025016538 A5 JP2025016538 A5 JP 2025016538A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011325843.0A CN114524878B (zh) | 2020-11-23 | 2020-11-23 | 一种双特异性抗体及其用途 |
| CN202011325843.0 | 2020-11-23 | ||
| PCT/CN2021/132195 WO2022105924A1 (zh) | 2020-11-23 | 2021-11-22 | 一种双特异性抗体及其用途 |
| JP2023530940A JP7846110B2 (ja) | 2020-11-23 | 2021-11-22 | 二重特異性抗体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530940A Division JP7846110B2 (ja) | 2020-11-23 | 2021-11-22 | 二重特異性抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025016538A JP2025016538A (ja) | 2025-02-04 |
| JP2025016538A5 true JP2025016538A5 (https=) | 2025-06-05 |
Family
ID=81618526
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530940A Active JP7846110B2 (ja) | 2020-11-23 | 2021-11-22 | 二重特異性抗体及びその使用 |
| JP2024185456A Pending JP2025016538A (ja) | 2020-11-23 | 2024-10-21 | 二重特異性抗体及びその使用 |
| JP2024185455A Pending JP2025016537A (ja) | 2020-11-23 | 2024-10-21 | 二重特異性抗体及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530940A Active JP7846110B2 (ja) | 2020-11-23 | 2021-11-22 | 二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185455A Pending JP2025016537A (ja) | 2020-11-23 | 2024-10-21 | 二重特異性抗体及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240002540A1 (https=) |
| EP (3) | EP4691565A2 (https=) |
| JP (3) | JP7846110B2 (https=) |
| KR (2) | KR20230117160A (https=) |
| CN (4) | CN114524878B (https=) |
| AU (2) | AU2021383901B2 (https=) |
| CA (1) | CA3199721A1 (https=) |
| WO (1) | WO2022105924A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114573703A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种t细胞衔接器治疗剂的开发和应用 |
| CN114573702A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种新型肿瘤衔接器治疗药物的开发和应用 |
| US11912771B2 (en) | 2021-03-09 | 2024-02-27 | Cdr-Life Ag | MAGE-A4 peptide-MHC antigen binding proteins |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| CN120712345A (zh) * | 2022-12-30 | 2025-09-26 | 上药生物治疗（香港）有限公司 | 表达趋化因子受体的细胞及其用途 |
| AU2024239034A1 (en) * | 2023-03-18 | 2025-09-25 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-her3/muc1 antibodies and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| WO2006132670A2 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| EP1898529A1 (en) | 2005-06-28 | 2008-03-12 | Pioneer Corporation | Broadcast receiving apparatus, interference detecting apparatus and interference detecting method |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| EP2552747A1 (de) | 2010-03-30 | 2013-02-06 | Behr GmbH & Co. KG | Temperierelement und temperiervorrichtung für ein fahrzeug |
| PL2606064T3 (pl) * | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| CN105121467B (zh) * | 2012-12-03 | 2019-07-05 | 诺夫免疫股份有限公司 | 抗cd47抗体及其使用方法 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| US20180171017A1 (en) | 2015-06-05 | 2018-06-21 | Chugai Seiyaku Kabushiki Kaisha | Combined use of immune activators |
| US10072088B2 (en) | 2015-08-17 | 2018-09-11 | Janssen Pharmaceutica, Nv | Anti-BCMA antibodies and uses thereof |
| AU2016378573A1 (en) | 2015-12-22 | 2018-07-19 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia |
| US11072666B2 (en) * | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| CN111201031B (zh) * | 2017-08-25 | 2024-11-01 | 诺夫免疫股份有限公司 | 抗CD47 x抗间皮素抗体及其使用方法 |
| JPWO2019244973A1 (ja) * | 2018-06-20 | 2021-07-08 | 中外製薬株式会社 | 標的細胞に対する免疫反応を活性化する方法およびその組成物 |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CN111454357B (zh) | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技（成都）有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
| CN112062855B (zh) * | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
| CN114573702A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种新型肿瘤衔接器治疗药物的开发和应用 |
| CN114573703A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种t细胞衔接器治疗剂的开发和应用 |
-
2020
- 2020-11-23 CN CN202011325843.0A patent/CN114524878B/zh active Active
- 2020-11-23 CN CN202410934007.4A patent/CN118878693A/zh active Pending
- 2020-11-23 CN CN202410934201.2A patent/CN118878694A/zh active Pending
-
2021
- 2021-11-22 WO PCT/CN2021/132195 patent/WO2022105924A1/zh not_active Ceased
- 2021-11-22 EP EP25205645.2A patent/EP4691565A2/en active Pending
- 2021-11-22 KR KR1020237021199A patent/KR20230117160A/ko active Pending
- 2021-11-22 CA CA3199721A patent/CA3199721A1/en active Pending
- 2021-11-22 EP EP25177852.8A patent/EP4591941A3/en active Pending
- 2021-11-22 JP JP2023530940A patent/JP7846110B2/ja active Active
- 2021-11-22 AU AU2021383901A patent/AU2021383901B2/en active Active
- 2021-11-22 EP EP21894071.6A patent/EP4249514A4/en active Pending
- 2021-11-22 KR KR1020257013696A patent/KR20250060324A/ko active Pending
- 2021-11-22 US US18/038,159 patent/US20240002540A1/en active Pending
- 2021-11-22 CN CN202180078861.XA patent/CN116490614A/zh active Pending
-
2024
- 2024-10-21 JP JP2024185456A patent/JP2025016538A/ja active Pending
- 2024-10-21 JP JP2024185455A patent/JP2025016537A/ja active Pending
-
2025
- 2025-05-08 AU AU2025203320A patent/AU2025203320A1/en active Pending
- 2025-06-05 US US19/229,907 patent/US20250346685A1/en active Pending